{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T01:52:34Z","timestamp":1791078754228,"version":"4.1.0"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2006,7,1]],"date-time":"2006-07-01T00:00:00Z","timestamp":1151712000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2006,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Long-term effects of risedronate on bone mineralization density distribution in triple transiliac crest biopsies of osteoporotic women were evaluated. In this double-blinded study, 3- and 5-year treatment with risedronate increased the degree and homogeneity of mineralization without producing hypermineralization. These changes at the material level of bone could contribute to risedronate's antifracture efficacy.<\/jats:p>\n               <jats:p>Introduction: Risedronate, a nitrogen-containing bisphosphonate, is widely used in the treatment of osteoporosis. It reduces bone turnover, increases BMD, and decreases fracture risk. To date, there are no data available on the long-term effects of risedronate on bone mineralization density distribution (BMDD) in humans.<\/jats:p>\n               <jats:p>Materials and Methods: Osteoporotic women enrolled in the VERT-NA trial received either risedronate (5 mg\/day, orally) or placebo for up to 5 years. All subjects received calcium and vitamin D supplementation if deficient at baseline. Triple iliac crest biopsies were collected from a subset of these subjects at baseline and 3 and 5 years. BMDD was measured in these biopsies using quantitative backscattered electron imaging, and the data were also compared with a normal reference group.<\/jats:p>\n               <jats:p>Results: At baseline, both risedronate and placebo groups had a lower degree and a greater heterogeneity of mineralization as well as an increase in low mineralized bone compared with the normal reference group. The degree of mineralization increased significantly in the risedronate as well as in the placebo group after 3- and 5-year treatment compared with baseline. However, the degree of mineralization did not exceed that of normal. Three-year treatment with risedronate significantly increased the homogeneity of mineralization and slightly decreased low mineralized bone compared with placebo. Surprisingly with 5-year risedronate treatment, heterogeneity of mineralization increased compared with 3-year treatment, which might indicate an increase in newly formed bone.<\/jats:p>\n               <jats:p>Conclusions: Long-term treatment with risedronate affects the homogeneity and degree of mineralization without inducing hypermineralization of the bone matrix. These changes at the material level of the bone matrix may contribute to risedronate's antifracture efficacy in osteoporotic patients.<\/jats:p>","DOI":"10.1359\/jbmr.060401","type":"journal-article","created":{"date-parts":[[2006,7,4]],"date-time":"2006-07-04T05:47:20Z","timestamp":1151992040000},"page":"1106-1112","source":"Crossref","is-referenced-by-count":109,"title":["Effects of 3- and 5-Year Treatment With Risedronate on Bone Mineralization Density Distribution in Triple Biopsies of the Iliac Crest in Postmenopausal Women"],"prefix":"10.1093","volume":"21","author":[{"given":"Ruth","family":"Zoehrer","sequence":"first","affiliation":[{"name":"Ludwig Boltzmann Institute of Osteology at the Hanusch Hospital of WGKK and AUVA Trauma Centre Meidling, and 4th Medical Department, Hanusch Hospital, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Roschger","sequence":"additional","affiliation":[{"name":"Ludwig Boltzmann Institute of Osteology at the Hanusch Hospital of WGKK and AUVA Trauma Centre Meidling, and 4th Medical Department, Hanusch Hospital, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleftherios P","family":"Paschalis","sequence":"additional","affiliation":[{"name":"Ludwig Boltzmann Institute of Osteology at the Hanusch Hospital of WGKK and AUVA Trauma Centre Meidling, and 4th Medical Department, Hanusch Hospital, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jochen G","family":"Hofstaetter","sequence":"additional","affiliation":[{"name":"Ludwig Boltzmann Institute of Osteology at the Hanusch Hospital of WGKK and AUVA Trauma Centre Meidling, and 4th Medical Department, Hanusch Hospital, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erich","family":"Durchschlag","sequence":"additional","affiliation":[{"name":"Ludwig Boltzmann Institute of Osteology at the Hanusch Hospital of WGKK and AUVA Trauma Centre Meidling, and 4th Medical Department, Hanusch Hospital, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Fratzl","sequence":"additional","affiliation":[{"name":"Department of Biomaterials, Max Planck Institute of Colloids and Interfaces, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Phipps","sequence":"additional","affiliation":[{"name":"Procter & Gamble Pharmaceuticals, Mason, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Klaushofer","sequence":"additional","affiliation":[{"name":"Ludwig Boltzmann Institute of Osteology at the Hanusch Hospital of WGKK and AUVA Trauma Centre Meidling, and 4th Medical Department, Hanusch Hospital, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2009,12,4]]},"reference":[{"key":"2024013019383724100_bib1","doi-asserted-by":"crossref","first-page":"4118","DOI":"10.1210\/jcem.85.11.6953","article-title":"Fracture risk reduction with alendronate in women with osteoporosis: The Fracture Intervention Trial. FIT Research Group","volume":"85","author":"Black","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"2024013019383724100_bib2","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jama.282.14.1344","article-title":"Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: A randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group","volume":"282","author":"Harris","year":"1999","journal-title":"JAMA"},{"issue":"Suppl 2","key":"2024013019383724100_bib3","first-page":"S203","article-title":"BMD changes explains only a fraction of theobserved fracture risk reduction in risedronate-treated patients","volume":"11","author":"Watts","year":"2000","journal-title":"Osteoporos Int"},{"key":"2024013019383724100_bib4","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1385\/JCD:7:3:255","article-title":"Relationship between changes in bone mineral density and vertebral fracture risk associated with risedronate: Greater increases in bone mineral density do not relate to greater decreases in fracture risk","volume":"7","author":"Watts","year":"2004","journal-title":"J Clin Densitom"},{"key":"2024013019383724100_bib5","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1185\/030079905X41390","article-title":"How useful are measurements of BMD and bone turnover?","volume":"21","author":"Miller","year":"2005","journal-title":"Curr Med Res Opin"},{"key":"2024013019383724100_bib6","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0002-9343(01)01124-X","article-title":"Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs","volume":"112","author":"Cummings","year":"2002","journal-title":"Am J Med"},{"key":"2024013019383724100_bib7","first-page":"1","article-title":"The long-term predictive value of bone mineral density measurements for fracture risk is independent of the site of measurement and the age at diagnosis: Results from the Prospective Epidemiological Risk Factors study","volume":"28","author":"Bagger","year":"2005","journal-title":"Osteoporos Int"},{"key":"2024013019383724100_bib8","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1359\/JBMR.050814","article-title":"Relationship between changes in BMD and nonvertebral fracture incidence associated with risedronate: Reduction in risk of nonvertebral fracture is not related to change in BMD","volume":"20","author":"Watts","year":"2005","journal-title":"J Bone Miner Res"},{"key":"2024013019383724100_bib9","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1359\/JBMR.0301228","article-title":"Relationship between changes in bone mineral density and fracture risk reduction with antiresorptive drugs. Some issues with meta-analyses","volume":"19","author":"Delmas","year":"2004","journal-title":"J Bone Miner Res"},{"key":"2024013019383724100_bib10","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1039\/B402005G","article-title":"Structure and mechanical quality of the collagen-mineral nano-composite in bone","volume":"14","author":"Fratzl","year":"2004","journal-title":"J Mater Chem"},{"key":"2024013019383724100_bib11","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S8756-3282(98)00112-4","article-title":"Validation of quantitative backscattered electron imaging for the measurement of mineral density distribution in human bone biopsies","volume":"23","author":"Roschger","year":"1998","journal-title":"Bone"},{"key":"2024013019383724100_bib12","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/S8756-3282(02)00973-0","article-title":"Constant mineralization density distribution in cancellous human bone","volume":"32","author":"Roschger","year":"2003","journal-title":"Bone"},{"key":"2024013019383724100_bib13","first-page":"75","article-title":"A new scanning electron microscopy approach to the quantification of bone mineral distribution: Backscattered electron image grey-levels correlated to calcium K alpha-line intensities","volume":"9","author":"Roschger","year":"1995","journal-title":"Scanning Microsc"},{"key":"2024013019383724100_bib14","volume-title":"Bone Histomorphometry","author":"Fink-Eriksen","year":"1994"},{"key":"2024013019383724100_bib15","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1210\/jc.2002-021988","article-title":"Effects of intermittent parathyroid hormone administration on bone mineralization density in iliac crest biopsies from patients with osteoporosis: A paired study before and after treatment","volume":"88","author":"Misof","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"2024013019383724100_bib16","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S8756-3282(01)00485-9","article-title":"Alendronate increases degree and uniformity of mineralization in cancellous bone and decreases the porosity in cortical bone of osteoporotic women","volume":"29","author":"Roschger","year":"2001","journal-title":"Bone"},{"key":"2024013019383724100_bib17","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.bone.2004.10.006","article-title":"Differential effects of alendronate treatment on bone from growing osteogenesis imperfecta and wild-type mouse","volume":"36","author":"Misof","year":"2005","journal-title":"Bone"},{"key":"2024013019383724100_bib18","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S8756-3282(97)00018-5","article-title":"Mineralization of cancellous bone after alendronate and sodium fluoride treatment: A quantitative backscattered electron imaging study on minipig ribs","volume":"20","author":"Roschger","year":"1997","journal-title":"Bone"},{"key":"2024013019383724100_bib19","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1098\/rstb.1984.0042","article-title":"Effects of differences in mineralization on the mechanical properties of bone","volume":"304","author":"Currey","year":"1984","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"2024013019383724100_bib20","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S8756-3282(00)00376-8","article-title":"Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women","volume":"27","author":"Boivin","year":"2000","journal-title":"Bone"},{"key":"2024013019383724100_bib21","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s00223-004-0039-7","article-title":"Five years of treatment with risedronate and its effects on bone safety in women with postmenopausal osteoporosis","volume":"75","author":"Ste-Marie","year":"2004","journal-title":"Calcif Tissue Int"},{"key":"2024013019383724100_bib22","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S8756-3282(02)00869-4","article-title":"Effects of long-term risedronate on bone quality and bone turnover in women with postmenopausal osteoporosis","volume":"31","author":"Eriksen","year":"2002","journal-title":"Bone"},{"key":"2024013019383724100_bib23","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/j.bone.2004.05.025","article-title":"Bone mineralization density and femoral neck fragility","volume":"35","author":"Loveridge","year":"2004","journal-title":"Bone"},{"key":"2024013019383724100_bib24","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1359\/JBMR.040920","article-title":"Treatment with once-weekly alendronate 70mg compared with once-weekly risedronate 35mg in women with postmenopausal osteoporosis: A randomized double-blind study","volume":"20","author":"Rosen","year":"2005","journal-title":"J Bone Miner Res"},{"key":"2024013019383724100_bib25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bone.2005.03.017","article-title":"The effect of risedronate on bone mineralization as measured by micro-computed tomography with synchrotron radiation: Correlation to histomorphometric indices of turnover","volume":"37","author":"Borah","year":"2005","journal-title":"Bone"},{"key":"2024013019383724100_bib26","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1021\/nl051584b","article-title":"Nanoscale deformation mechanisms in bone","volume":"5","author":"Gupta","year":"2005","journal-title":"Nano Lett"},{"key":"2024013019383724100_bib27","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/nmat1545","article-title":"From brittle to ductile fracture of bone","volume":"5","author":"Peterlik","year":"2006","journal-title":"Nat Mater"},{"key":"2024013019383724100_bib28","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/S8756-3282(02)00946-8","article-title":"Long-term efficacy of risedronate: A 5-year placebo-controlled clinical experience","volume":"32","author":"Sorensen","year":"2003","journal-title":"Bone"}],"container-title":["Journal of Bone and Mineral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1359%2Fjbmr.060401","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/21\/7\/1106\/56478781\/5650210714.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/21\/7\/1106\/56478781\/5650210714.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T14:46:32Z","timestamp":1710341192000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmr\/article\/21\/7\/1106-1112\/7593212"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,7,1]]},"references-count":28,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2009,12,4]]},"published-print":{"date-parts":[[2006,7,1]]}},"URL":"https:\/\/doi.org\/10.1359\/jbmr.060401","relation":{},"ISSN":["0884-0431","1523-4681"],"issn-type":[{"value":"0884-0431","type":"print"},{"value":"1523-4681","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2006,7,1]]},"published":{"date-parts":[[2006,7,1]]}}}